Please assess the completion status of the following clinical trial:

Trial Title: Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy participants 6 months to 45 years of age at enrollment~2. Participants/Parent(s)/LAR who have voluntarily given informed consent/assent~3. Participants/Parent(s)/LAR willing to follow the study procedures of the study and available for the entire duration of the study~Exclusion Criteria:~1. Child with a congenital abnormality~2. Participant who has already received meningococcal conjugate vaccine~3. Participants concomitantly enrolled or scheduled to be enrolled in another trial~4. Known history of immune function disorders including immunodeficiency diseases (Known HIV infection or other immune function disorders)~5. Chronic use of systemic steroids (\>2 mg/kg/day or \>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs~6. Receipt of blood or blood-derived products in the past 3 months~7. Participant with a previously ascertained or suspected disease caused by S. Typhi (confirmed either clinically, serologically or microbiologically)~8. Participant who has had household contact with and/or intimate exposure to an individual with laboratory-confirmed S. Typhi~9. Individual who has previously received a typhoid vaccine~10. Participant who has received other vaccines from 1 month prior to test vaccination or planned to receive any vaccine within 1 month (except a measles containing vaccine as per government vaccination campaign)~11. Known history or allergy to vaccines or other medications~12. History of uncontrolled coagulopathy or blood disorders~13. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives~14. Any female participant who is lactating, pregnant\* or planning for pregnancy during the course of study period~15. Participants/Parent(s)/LAR planning to move from the study area before the end of study period~16. As per Investigator's medical judgement individual could be excluded from the study in spite of meeting all inclusion/exclusion criteria mentioned above

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Vi-DT Multi-dose (Type: EXPERIMENTAL): * 750 participants (6 mo - 45 yrs)~* Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~* Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (multi-dose formulation Vi-DT contains preservative 2 PE)~* Mode of Administration: Intramuscular injection~* Frequency of administration: Once
- Vi-DT Single-dose (Type: EXPERIMENTAL): * 750 participants (6 mo - 45 yrs)~* Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~* Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (single dose formulation Vi-DT without any preservative)~* Mode of Administration: Intramuscular injection~* Frequency of administration: Once
- Control (Type: ACTIVE_COMPARATOR): * 300 participants (6 mo - 45 yrs)~* Dose: 0.5mL, Locally available Meningococcal conjugate vaccine~* Dosage form: Lyophilized white powder~* Mode of Administration: Intramuscular injection~* Frequency of administration: Once (For participants 6 months to 1 year, one more dose will be provided after the study unblinding)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete